23. Februar 2012
Background: To determine the predictive value of the immature granulocyte count and the immature myeloid information in neonatal early onset...Read more
29. November 2011
Background: The interest in neonatal screening for lysosomal storage disorders has increased substantially because of newly developed enzyme replacement...Read more
1. September 2011
BACKGROUND: Interest in lysosomal storage disorders, a collection of more than 40 inherited metabolic disorders, has increased because of new...Read more
1. März 2011
ABSTRACT: To achieve clinical validation of cutoff values for newborn screening by tandem mass spectrometry through a worldwide collaborative...Read more
15. Oktober 2010
BACKGROUND: the National Austrian Newborn Screening Program for inherited metabolic and endocrinologic disorders was introduced in 1966. The program continuously...Read more
15. April 2010
Lysosomal storage disorders are just beginning to be routinely screened using enzyme activity assays involving dried blood spots and...Read more
29. November 2009
Background: Mutations in the alpha-l-iduronidase A (IDUA) gene cause mucopolysaccharidosis type I (MPS I), a progressive multisystem disorder with...Read more
Started in 2013, ARCHIMEDlife is an independent highly-innovative company dedicated in providing and developing diagnostic services from Inborn Errors of Metabolism to Oncological Diseases. Our commitment is to provide better and faster high-quality laboratory tests for you and your family.
Our diagnostic laboratory is offering services from Clinical Mass Spectrometry to Next-Generation Sequencing. We have international collaborations with physicians, clinical researchers and industry specialized in personalized health care.
We are dedicated to the development of novel laboratory tests to make actionable health information accessible at the time it matters.